Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Completed 30Recruiting 16Terminated 7Unknown 5Not yet recruiting 5Active not recruiting 5Withdrawn 4Suspended 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1CNS 1

Conditions

Breast Neoplasms 2Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Leukemia 1Disease 1Central Nervous System Neoplasms 1

Interventions

pembrolizumab 438Carboplatin 321Nivolumab 293Cyclophosphamide 285Specimen Handling 257Paclitaxel 249Magnetic Resonance Spectroscopy 249Cisplatin 248Radiotherapy 218Dexamethasone 183Gemcitabine 177Biopsy 177durvalumab 169atezolizumab 149Doxorubicin 140Rituximab 138Lenalidomide 135Docetaxel 131Ipilimumab 130Bevacizumab 128Radiation 121Capecitabine 117Etoposide 116Oxaliplatin 114Fluorouracil 110Pemetrexed 109Radiosurgery 108fludarabine 106venetoclax 102Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × neratinib × Clear all
NCT04502602 2026-05-11

iNNOVATE

Virginia Commonwealth University

Phase 1 Active not recruiting
18 enrolled
Gynecologic

Ovarian Neoplasms

NCT03377387 2026-04-16

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
34 enrolled
Breast

Breast Neoplasms

NCT03065387 2026-01-12

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
93 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02932280 2025-12-05

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
14 enrolled
CNSLymphoidOther hematologic neoplasm

Disease, Leukemia, Lymphoma, Recurrence, Central Nervous System Neoplasms

NCT05252988 2025-04-01

DIANER

Spanish Breast Cancer Research Group

Phase 2 Active not recruiting
177 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡